Current cardiac drug safety assessments focus on hERG channel block and QT prolongation for evaluating arrhythmic risks. whereas the optogenetic approach focuses on the action potential (AP) waveform generated by a monolayer of human cardiomyocytes beating synchronously. thus assessing the contribution of several ion channels on the overall drug effect. This novel tool provides arrhyt... https://www.rawafricaonline.com/